SELLAS Life Sciences (SLS) Operating Expenses (2010 - 2026)

For the trailing twelve months through Jun 30, 2026, Operating Expenses at SELLAS Life Sciences was $35.22 million, up 29.6% year-over-year; for FY2025, it came in at $28.27 million, down 10.3% from FY2024.

• Annual Operating Expenses has declined for three consecutive years, though with a five-year compound annual growth rate of 8.4% (FY2020 to FY2025).
• In prior years, SELLAS Life Sciences' Operating Expenses was $31.51 million in FY2024 (-16.8%), $37.87 million in FY2023 (-11.8%), $42.95 million in FY2022 (+30.6%) and $32.89 million in FY2021 (+74.2%).
• The Q2 2026 figure stands as the highest quarterly Operating Expenses since Q1 2023.
• On a year-over-year basis, Operating Expenses has increased in each of the last three quarters, with growth averaging 4.9% over the last eight quarters.
• The strongest year-over-year quarter for Operating Expenses in the past five years was Q1 2022, with growth of 123.2%; the weakest was Q1 2025, with a decline of 37.1%.
• According to Business Quant data, Operating Expenses for the three prior quarters was $9.25 million (Q1 2026), $8.26 million (Q4 2025) and $7.08 million (Q3 2025).